Oyster Point Pharma Return on Equity

Oyster Point Pharma (OYST) currently reports a ROE of 851.15%. That is above the Healthcare sector average of 13.26%. Use the charts on this page to explore Oyster Point Pharma's ROE history and peer comparisons.

Oyster Point Pharma's ROE of 851.15% is higher than the Healthcare sector average of 13.26%. That is roughly 6317.4% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Oyster Point Pharma's current 851.15% should be judged against Healthcare norms (sector average: 13.26%) and against OYST's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 851.15%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.26%. From there, open related valuation or income-statement pages for Oyster Point Pharma, and consider following OYST for alerts when major investors trade the stock.

Oyster Point Pharma is classified in the Healthcare sector. On ROE, it currently shows 851.15% versus a sector average near 13.26%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing OYST with unrelated industries.